Revenue: USD 815.6 million (up 8.7% from Q3 2023).
Net income: USD 68.1 million (up from a loss of USD 217.7 million in Q3 2023).
Margin: 8.4% (up from net loss in Q3 2023). The transition to profitability was primarily driven by cost reductions.
EPS: USD 0.74 (up from loss of USD 2.39 in Q3 2023).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Sales were in line with analyst forecasts. Earnings per share (EPS) were 16% lower than analysts expected.
Looking ahead, revenues are expected to increase by an average of 8.9% per year over the next three years, compared to a growth forecast of 6.7% for the U.S. healthcare industry.
Performance of the American healthcare industry.
The company's stock price has fallen 17% from a week ago.
You should learn about the 1 warning sign we've spotted with Acadia Healthcare Company.
Do you have feedback about this article? Interested in its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
